Singapore’s multi-phase national precision medicine programme has chosen the two companies to provide whole-genome sequencing services.
Nasdaq-listed biotech company Illumina and a consortium led by Singapore- and Palo Alto-based precision oncology and health company Lucence have been selected to provide whole-genome sequencing services for the SG-INSIGHT study under Phase III of Singapore’s National Precision Medicine programme.
Expected to include one in ten Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.
This is a transition from studying genomics primarily in healthy volunteers to studying those with a broad range of medical conditions. By connecting genomic information with real-world health data, the study aims to understand disease and treatment responses, support the responsible introduction of genetic screening in Singapore’s public healthcare system, and help healthcare become more tailored to individuals over time.
“Singapore is showing what the future of precision medicine can look like at national scale,” said Illumina chief executive Jacob Thaysen. “By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease.”
Illumina will perform the sequencing in Singapore through its local genomics facility where scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing, and genomic data analysis.
Lucence, working with QIAGEN and Ultima Genomics, will provide end-to-end programme management and local operational leadership, integrating its partners’ technologies within its clinical laboratory operations. QIAGEN will support automated DNA extraction and library preparation, while Ultima Genomics will provide sequencing and genomic analysis capabilities.
“Genetics is not one-size-fits-all. For precision medicine to work for people in Asia, we need evidence from Asian populations. Singapore offers a particularly valuable setting for this work,” said Tan Min-Han, founding chief executive of the Lucence Group. “Our Chinese, Malay and Indian populations bring significant genetic diversity together within a single healthcare and research ecosystem, alongside longitudinal health information and established research infrastructure.”
Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore’s multi-phase National Precision Medicine (NPM) programme. Administered by the Ministry of Health, PRECISE works with research, clinical and industry partners to generate insights into Asian genomics and translate these into better health outcomes.



